STAB Stock Analysis
ST
Uncovered
Statera Biopharma Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Statera Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is headquartered in Fort Collins, Colorado and currently employs 46 full-time employees. The company went IPO on 2006-07-21. The firm is focused on developing immunotherapies autoimmune, neutropenia/anemia, emerging viruses and cancers. Its Advanced Immunomodulating Multi-Component System (AIMS) platform is designed to rebalance the body's immune system and restore homeostasis. Its platforms of toll-like receptor (TLR) agonists include R4 and TLR9 antagonists, and the TLR5 agonists, Entolimod and GP532. Through its AIMS platform, the Company develops product candidates, which include STAT-200 and STAT-600 AIMS programs. Its STAT-200 program include STAT-201 is focused on treatment of Crohn’s disease. The firm has clinical programs for Crohn’s disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401) and COVID-19 (STAT-205).